Rhodex-Puguet has long been a leader in the specialty chemicals market. Its success has been attributed to heavy investment in R&D, but lately, instead of producing innovative, new products, it’s having problems with missed deadlines, overworked staff and unclear expectations. So what does a firm do when it finds its R&D suddenly stands for Returns Declining? Professor Arnoud De Meyer challenges you to find the answers.
Content: Case Study
Author: Arnoud De Meyer
Source: INSEAD
Subjects: Industry Specific, Strategy
Industry: Pharmaceutical
Company: Rhodex-Puguet S.A.
Author: Arnoud De Meyer
Source: INSEAD
Subjects: Industry Specific, Strategy
Industry: Pharmaceutical
Company: Rhodex-Puguet S.A.
Like this content? Why not share it?
There Are No Comments
Click to Add the First »
Click to Add the First »